Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CABOZANTINIB S-MALATE Cause Dysgeusia? 777 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 777 reports of Dysgeusia have been filed in association with CABOZANTINIB S-MALATE (CABOMETYX). This represents 2.0% of all adverse event reports for CABOZANTINIB S-MALATE.

777
Reports of Dysgeusia with CABOZANTINIB S-MALATE
2.0%
of all CABOZANTINIB S-MALATE reports
27
Deaths
94
Hospitalizations

How Dangerous Is Dysgeusia From CABOZANTINIB S-MALATE?

Of the 777 reports, 27 (3.5%) resulted in death, 94 (12.1%) required hospitalization, and 2 (0.3%) were considered life-threatening.

Is Dysgeusia Listed in the Official Label?

Yes, Dysgeusia is listed as a known adverse reaction in the official FDA drug label for CABOZANTINIB S-MALATE.

What Other Side Effects Does CABOZANTINIB S-MALATE Cause?

Diarrhoea (8,282) Fatigue (6,819) Off label use (5,245) Nausea (4,341) Decreased appetite (4,076) Blood pressure increased (2,939) Malignant neoplasm progression (2,718) Palmar-plantar erythrodysaesthesia syndrome (2,706) Weight decreased (2,657) Stomatitis (2,560)

What Other Drugs Cause Dysgeusia?

NIRMATRELVIR\RITONAVIR (7,381) SUNITINIB MALATE (1,226) SODIUM (1,216) LENALIDOMIDE (1,180) LIFITEGRAST (1,067) CLARITHROMYCIN (717) VISMODEGIB (706) ADALIMUMAB (674) PALBOCICLIB (620) OMEPRAZOLE (601)

Which CABOZANTINIB S-MALATE Alternatives Have Lower Dysgeusia Risk?

CABOZANTINIB S-MALATE vs CAFFEINE CABOZANTINIB S-MALATE vs CALASPARGASE PEGOL CABOZANTINIB S-MALATE vs CALASPARGASE PEGOL-MKNL CABOZANTINIB S-MALATE vs CALCIFEDIOL CABOZANTINIB S-MALATE vs CALCIPOTRIENE

Related Pages

CABOZANTINIB S-MALATE Full Profile All Dysgeusia Reports All Drugs Causing Dysgeusia CABOZANTINIB S-MALATE Demographics